Search

Oct 27, 2024
Vera's CEO discusses the 96-week follow up results for Atacicept in IgAN that were presented this weekend at Kidney Week in San Diego
Marshall Fordyce discusses the results for this fusion protein that binds to both BAFF and APRIL. The company says it saw eGFR...

Feb 13, 2024
Taking a deep dive into the IgA nephropathy (IgAN) space with the CEO of Vera Therapeutics
Marshall Fordyce describes the rationale of targeting both BAFF and APRIL as a B-cell modulator for IgAN.